Mounjaro for weight loss: what the evidence says about results and side effects

What SURMOUNT-1 actually found, results and tolerability together

The phase 3 SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no diabetes to tirzepatide or placebo over 72 weeks. At 15mg, average weight loss reached around 20–21% of body weight. At 10mg it was closer to 19%, and at 5mg roughly 15%. Those are mean figures (some participants lost more, some less) and the trial ran alongside a reduced-calorie diet and increased physical activity, as the medicine is licensed to be used.

Tolerability data from the same trial matter as much as the efficacy numbers. Around 4–7% of participants discontinued because of side effects depending on the dose arm, compared with roughly 3% on placebo. The majority of discontinuations were GI-related. That tells you the side effects are real, that most people continue treatment regardless, and that a minority find them difficult enough to stop. Knowing this going in (rather than being surprised at week three) is part of what a proper clinical consultation is for. Our prescribers at nume discuss suitability and expected tolerability as a core part of that conversation; you can start a free consultation here.

The side effects people actually report, and which ones to watch

Nausea tops almost every review of mounjaro experience, followed by diarrhoea, constipation, vomiting and indigestion. These tend to cluster in the first few days after starting or stepping up a dose, then ease as the body adjusts. Injection-site reactions, fatigue and headache are also reported, though less consistently. For a fuller breakdown of the pattern by severity and frequency, the mounjaro side effects overview on this site covers each one in detail.

Two side effects sit in a different category because they require prompt attention rather than watchful waiting. First: acute pancreatitis. In its January 2026 Drug Safety Update, the MHRA confirmed that severe, persistent stomach pain, especially if it travels towards the back with or without vomiting, should trigger same-day medical assessment. Second: gallbladder problems, including gallstones and cholecystitis, which appeared at a slightly higher rate in tirzepatide trial participants than in the placebo group. Neither is common, but both are serious enough that the guidance is clear. A separate question patients regularly raise is hair thinning during rapid weight loss, which appears to be a physiological response to calorie deficit rather than a direct drug effect, the distinction matters for how it's managed.

When to get medical help, and how to report what you experience

The NHS sets out several situations where mounjaro users should seek urgent care rather than waiting for a scheduled review. Severe abdominal pain that radiates to the back is the highest priority, given the pancreatitis signal. Other triggers: signs of dehydration from persistent vomiting or diarrhoea (dark urine, dizziness, very low urine output), symptoms of a serious allergic reaction (swelling of the face or throat, difficulty breathing), and any sudden deterioration in mood or thoughts of self-harm. None of these should be managed by adjusting the dose independently or waiting to see, they need clinical assessment the same day.

For side effects that are uncomfortable but not urgent, the right move is to raise them at your next clinical review, where a prescriber can weigh up whether to slow the titration schedule or consider other adjustments. If you want to understand what is and isn't serious before your next check-in, the mounjaro safety overview and the NHS tirzepatide page both give clear reference points. You can also report any suspected side effect (or flag a suspect seller) via the MHRA Yellow Card scheme; the scheme actively relies on patient reports, not just clinician submissions. For questions specific to your own circumstances, the weight loss treatments overview or a direct message to our support team is the right starting point.

How reviews align with the clinical picture, and what that means for you

Online accounts of mounjaro for weight loss vary widely, partly because people begin at different doses, follow different titration speeds and have different baseline health profiles. Someone who lost 18% over a year at 10mg and had mild nausea for the first two weeks will describe a different experience from someone who moved too quickly through the dose schedule and had persistent GI symptoms. That variation is real, not a reason to dismiss either account. The detailed side-effect and weight loss data page unpacks how dose, titration pace and individual factors interact.

What the clinical evidence does establish clearly is that the medicines approved for weight management in the UK (including tirzepatide) have been tested in rigorous, large-scale trials with transparent tolerability reporting. NICE reviewed all of that data before recommending tirzepatide in TA1026, published December 2024. Private treatment through a GPhC-registered pharmacy like nume follows the same licensed indications: same medicine, same clinical standards, same supply chain. When your prescription is approved, the pen arrives the next working day in a plain DPD box, tracked to your door, the clinical rigour behind it isn't visible from the outside, but it's there. The clinical team, including our lead prescriber Mostafa Damghani, reviews every consultation personally before anything is dispatched.